FDA Clarifies the Line Between Wellness Software, CDS Software, and Regulated Medical Devices

Digital health companies often face a deceptively simple question early in development:

Is this software a medical device?

The answer can dramatically affect product strategy, development timelines, quality system expectations, validation planning, labeling, and commercialization. A product that appears to be a consumer wellness app or clinical workflow tool may still fall under FDA oversight depending on its intended use, claims, functionality, outputs, and user population.

FDA’s recent updates to its guidance on low-risk general wellness products and clinical decision support software provide useful clarification for companies building software-driven health products, wearables, remote monitoring tools, and clinical algorithms. The key takeaway is not that FDA is stepping away from digital health oversight. Rather, FDA is drawing clearer boundaries around when certain software functions may fall outside the medical device definition or qualify for enforcement discretion.

Intended Use Still Drives the Analysis

One of the most important reminders from the updated guidance is that intended use matters. The same underlying technology can be treated very differently depending on how it is positioned.

For example, software that tracks activity, sleep, recovery, stress, or general fitness may be a low-risk general wellness product if the claims stay within wellness boundaries. But if that same software is marketed to diagnose, monitor, treat, mitigate, or prevent a disease or condition, the regulatory analysis changes quickly.

This is especially important for products using physiologic sensing. FDA now provides more clarity that certain noninvasive sensing products may still fit within the general wellness framework when the outputs are intended only for wellness uses. These may include products that estimate or display parameters such as heart rate variability, oxygen saturation, blood pressure, or glucose-related information, but only if the product is noninvasive, not implanted, low risk, appropriately validated when displaying clinical-like values, and not intended to substitute for an FDA-authorized device.

That distinction is critical. A wearable that displays trends to support fitness, sleep, or recovery may be viewed differently from a product that alerts users to manage hypertension, detect a disease state, or make treatment decisions.

Claims, Labeling, and UI Matter as Much as the Algorithm

For digital health products, regulatory risk is not limited to the code.

Marketing copy, website language, onboarding screens, dashboards, notifications, disclaimers, user manuals, app store descriptions, sales decks, and customer support scripts can all affect intended use. A product may be technically designed as a wellness tool, but if the user interface or promotional claims suggest diagnostic or treatment use, the product may move into regulated medical device territory.

FDA’s updated general wellness guidance reinforces that products should not include claims, functionality, or outputs that prompt or guide specific clinical action or medical management. It also cautions against claims of clinical equivalence, “medical grade” performance, or substitution for an FDA-cleared, approved, or authorized device.

This creates an important design principle: regulatory strategy should be considered early, not after the product is built. Intended use should influence feature design, user messaging, data display, alert logic, validation strategy, and commercialization plans from the beginning.

CDS Software Must Support, Not Replace, Clinical Judgment

FDA’s updated clinical decision support guidance also provides important clarification for software used by healthcare professionals.

Certain CDS software may fall outside the device definition when it meets the statutory criteria, including that it is intended to support or provide recommendations to a healthcare professional and allows that healthcare professional to independently review the basis for the recommendation. In practical terms, the software should help inform clinical judgment, not replace it.

This distinction is especially important for AI-enabled tools. If a model provides a recommendation but does not give the healthcare professional enough information to understand the basis for that recommendation, the product may fail to qualify as non-device CDS. FDA emphasizes transparency, independent review, and the ability of the clinician to apply their own judgment.

For developers, this means the design of the explanation layer matters. Source attribution, patient-specific inputs, relevant guidelines, validation summaries, confidence information, limitations, and clear presentation of the basis for recommendations can all become important parts of the product architecture.

Time-Critical Decisions Remain Higher Risk

Another important theme is time sensitivity.

Software intended to support critical or time-sensitive decisions is less likely to be treated as non-device CDS because the healthcare professional may not have adequate time to independently review the basis for the recommendation. A tool that supports long-term care planning is very different from one that directs immediate escalation, triage, diagnosis, or treatment in an acute setting.

This has practical implications for product teams developing algorithms, dashboards, monitoring tools, or alerting systems. If the software output is designed to drive immediate action, the regulatory pathway may look very different than if the tool supports non-urgent review by a clinician.

Practical Takeaways for Digital Health Developers

For companies building wellness software, wearable products, SaMD, or CDS tools, the updated FDA guidance highlights several practical steps:

1. Define intended use early and make sure product functionality, labeling, and marketing stay aligned with that intended use.

2. Separate wellness claims from disease-related claims, especially when displaying physiologic data.

3. Be cautious with alerts, alarms, clinical thresholds, and recommendations that could imply diagnosis, monitoring, treatment, or medical management.

4. Validate displayed values when they mimic clinically used measurements.

5. For CDS tools, design the product so healthcare professionals can independently review the basis for recommendations.

6. Build transparency, usability, and human review into AI-enabled clinical software from the beginning.

7. Reassess regulatory classification whenever features, claims, user populations, or data inputs change.

The Bottom Line

FDA’s updated guidance is helpful, but it does not remove the need for careful regulatory and software planning. The boundary between a wellness product, non-device CDS, enforcement discretion, and a regulated medical device can be narrow.

For digital health companies, the safest approach is to treat regulatory classification as a product design input. The earlier the intended use, claims, data sources, UI behavior, validation plan, and risk controls are aligned, the easier it is to avoid costly redesigns, delays, or unexpected regulatory exposure later.

At MedTechWare, we help medical device and digital health teams think through these software, regulatory, cybersecurity, and quality considerations early so the product architecture supports both innovation and compliance.